Process Development for SHED Investigational Drug Manufacturing with Showa Denko Materials
First written in FY2023-Q2. 1 of 3 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「The Company entered into a joint development agreement with Nipro, a contract manufacturing services provider, and completed the technology transfer from S-Quatre.」
Development progressed toward the manufacture of SHED investigational products through the execution of a joint development agreement with Nipro and completion of the technology transfer. - FY2023-Q3RestatedAnnual report
「In addition, in September 2022 we entered into a basic transaction agreement with 昭和電工マテリアルズ㈱ concerning process development and clinical-trial drug manufacturing for regenerative medical products, accelerating development activities toward manufacturing clinical-trial drugs using the highly reliable, high-quality SHED master cell bank manufactured under the framework described above.」
The Company reconfirmed the acceleration of development toward manufacturing SHED investigational products using the SHED master cell bank, under the basic business agreement with Showa Denko Materials. - FY2023-Q2First statedAnnual report
「In addition, in September 2022 we entered into a basic transaction agreement with 昭和電工マテリアルズ㈱ concerning process development and clinical-trial drug manufacturing for regenerative medical products, accelerating development activities toward manufacturing clinical-trial drugs using the highly reliable, high-quality SHED master cell bank manufactured under the framework described above.」
Under a basic business agreement with Showa Denko Materials, the Company began activities toward process development and the manufacture of investigational products for regenerative medicine and related products, using the SHED master cell bank manufactured under the S-Quatre structure.